Zabihullah Wardak
General Practice · Lincoln, CANPI 1811249790
Payments from drug & device makers
Across 156 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Forte Bio-pharma LLC$2K
- AstraZeneca$483
- AbbVie$241
- Intra-sana Laboratories$202
- Lilly USA, LLC$187
- Takeda Pharmaceuticals U.S.A., Inc.$184
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,078100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Forte Bio-pharma LLC | 46 | $1,621 |
| AstraZeneca | 13 | $483 |
| AbbVie | 16 | $241 |
| Intra-sana Laboratories | 3 | $202 |
| Lilly USA, LLC | 10 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $184 |
| Boehringer Ingelheim | 9 | $182 |
| Ironwood Pharmaceuticals, Inc | 7 | $123 |
| GSK | 7 | $114 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Amgen(2 entities) | 5 | $94 |
| ANI Pharmaceuticals, Inc. | 1 | $83 |
| Esperion Therapeutics, Inc. | 1 | $73 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Nabriva Therapeutics, PLC | 3 | $43 |
| Abbott | 2 | $41 |
| Novo Nordisk | 2 | $36 |
| Pfizer | 1 | $32 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Nevro Corp. | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nalocet$1,083
- Prolate$1,083
- Reltone 200 Mg$141
- GLYCATE$141
- Reltone 400 Mg$141
- FARXIGA$135
How this compares
$4,078 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $125,068 |
| EliquisApixaban | 64 | $47,678 |
| OzempicSemaglutide | 31 | $43,780 |
| JanuviaSitagliptin Phosphate | 45 | $41,731 |
| XareltoRivaroxaban | 21 | $29,876 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $29,498 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $23,696 |
| EntrestoSacubitril/Valsartan | 26 | $22,177 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $21,828 |
| FarxigaDapagliflozin Propanediol | 31 | $21,160 |
| TradjentaLinagliptin | 14 | $16,239 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,440 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,270 |
| LinzessLinaclotide | 17 | $9,639 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $8,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $182 | $141,307127 claims |
| MerckJanuvia, Janumet, Janumet Xr | $23 | $87,25594 claims |
| PfizerEliquis | $32 | $47,67864 claims |
| Novo NordiskOzempic | $36 | $43,78031 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $114 | $39,76864 claims |
| AstraZenecaFarxiga, Symbicort | $483 | $23,57442 claims |
| NovartisEntresto | $14 | $22,17726 claims |
| AbbVieLinzess | $241 | $9,63917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Lincoln
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.